Article Information
History
- November 18, 2022.
Article Versions
- You are currently viewing Version 1 of this article (November 18, 2022 - 12:48).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Andrew P. Creagh*,1,2,
- Valentin Hamy3,
- Hang Yuan2,4,
- Gert Mertes1,2,4,
- Ryan Tomlinson5,
- Wen-Hung Chen5,
- Rachel Williams5,
- Christopher Llop6,
- Christopher Yee6,
- Mei Sheng Duh6,
- Aiden Doherty†,2,4,
- Luis Garcia-Gancedo†,3 and
- David A. Clifton†,1
- 1Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford, UK
- 2Big Data Institute, University of Oxford, UK
- 3Value Evidence and Outcomes (VEO), GSK, UK
- 4Nuffield Department of Population Health, University of Oxford, UK
- 5Value Evidence and Outcomes (VEO), GSK, US
- 6Analysis Group (AG), Boston, MA, USA
- ↵*Corresponding author: andrew.creagh{at}eng.ox.ac.uk;
Posted November 18, 2022.
Digital health technologies and machine learning augment patient reported outcomes to remotely characterise rheumatoid arthritis
